CATX -
Perspective Therapeutics, Inc.
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 2.12 -0.04 (-2.12%) |
0.0 (0.0%) |
0.0 (-0.24%) |
-0.01 (-0.72%) |
--- |
-0.04 (-2.12%) |
0.02 (0.94%) |
0.02 (0.94%) |
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Earnings & Ratios
- Basic EPS:
- -0.25
- Diluted EPS:
- -0.25
- Basic P/E:
- -8.3
- Diluted P/E:
- -8.3
- RSI(14) 1m:
- 53.12
- VWAP:
- 2.07
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium
Dec 04, 2025 12:00
Perspective Therapeutics to Participate in Upcoming December Conferences
Nov 20, 2025 12:00
Perspective Therapeutics to Participate in Upcoming November Conferences
Oct 31, 2025 11:00
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results
Oct 24, 2025 11:00
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds
Jul 23, 2025 13:26
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results
Jul 15, 2025 11:00
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
Jun 21, 2025 12:00
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results
Apr 17, 2025 11:00
Pharma-Biotech Market Development Analysis Report 2025: Growth Opportunities Shaped by a Convergence of Scientific Innovation, Regulatory Evolution, and Market Pressures
Apr 01, 2025 12:00
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
Mar 17, 2025 11:00